Department of Medical Oncology, Faculty of Medicine, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
Department of Medical Oncology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey.
Turk J Med Sci. 2022 Aug;52(4):1022-1032. doi: 10.55730/1300-0144.5404. Epub 2022 Aug 10.
Perioperative FLOT regimen is a standard of care in locally advanced operable gastric and GEJ adenocarcinoma. We aimed to determine the efficacy, prognostic factors of perioperative FLOT chemotherapy in real-life gastric and GEJ tumors.
The data of patients who were treated with perioperative FLOT chemotherapy were retrospectively analyzed from 34 different oncology centers in Turkey. Baseline clinical and demographic characteristics, pretreatment laboratory values, histological and molecular characteristics were recorded.
A total of 441 patients were included in the study. The median of age our study population was 60 years. The majority of patients with radiological staging were cT3-4N(+) (89.9%, n = 338). After median 13.5 months (IQR: 8.5-20.5) follow-up, the median overall survival was NR (95% CI, NR to NR), and median disease free survival was 22.9 (95% CI, 18.6 to 27.3) months. The estimated overall survival at 24 months was 62%. Complete pathological response (pCR) and near pCR was achieved in 23.8% of all patients. Patients with lower NLR or PLR have significantly longer median OS (p = 0.007 and p = 0.033, respectively), and patients with lower NLR have significantly longer median DFS (p = 0.039), but PLR level did not affect DFS (p = 0.062). The OS and DFS of patients with better ECOG performance scores and those who could receive FLOT as adjuvant chemotherapy instead of other regimens were found to be better. NLR was found to be independent prognostic factor for OS in the multivariant analysis. At least one adverse event reported in 57.6% of the patients and grade 3-4 toxicity was seen in 23.6% patients.
Real-life perioperative FLOT regimen in operable gastric and GEJ tumors showed similar oncologic outcomes compared to clinical trials. Better performance status, receiving adjuvant chemotherapy as same regimen, low grade and low NLR and PLR improved outcomes in real-life. However, in multivariate analysis, only NLR affected OS.
围手术期 FLOT 方案是局部可切除胃和胃食管交界处腺癌的标准治疗方案。我们旨在确定围手术期 FLOT 化疗在真实世界胃和胃食管交界处肿瘤中的疗效和预后因素。
从土耳其 34 个不同的肿瘤中心回顾性分析接受围手术期 FLOT 化疗的患者数据。记录基线临床和人口统计学特征、预处理实验室值、组织学和分子特征。
本研究共纳入 441 例患者。研究人群的中位年龄为 60 岁。大多数患者的影像学分期为 cT3-4N+(89.9%,n=338)。中位随访 13.5 个月(IQR:8.5-20.5)后,中位总生存期为未达到(95%CI,未达到-未达到),中位无病生存期为 22.9(95%CI,18.6-27.3)个月。估计 24 个月总生存率为 62%。所有患者中完全病理缓解(pCR)和接近 pCR 的比例为 23.8%。NLR 或 PLR 较低的患者中位 OS 明显更长(p=0.007 和 p=0.033),NLR 较低的患者中位 DFS 明显更长(p=0.039),但 PLR 水平对 DFS 无影响(p=0.062)。ECOG 表现评分较好且能够接受 FLOT 作为辅助化疗而非其他方案的患者的 OS 和 DFS 更好。多变量分析显示 NLR 是 OS 的独立预后因素。57.6%的患者至少报告了一种不良事件,23.6%的患者发生了 3-4 级毒性。
在可切除的胃和胃食管交界处肿瘤中,真实世界围手术期 FLOT 方案显示出与临床试验相似的肿瘤学结果。更好的表现状态、接受相同方案的辅助化疗、较低的分级和 NLR、PLR 改善了真实世界中的结果。然而,在多变量分析中,只有 NLR 影响 OS。